Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 369 Carcinoma, Non-Small-Cell Lung 315 Neoplasms 289 Prostatic Neoplasms 245 Colorectal Neoplasms 214 Multiple Myeloma 182 Lung Neoplasms 170 Neoplasm Metastasis 152 Leukemia, Myeloid, Acute 137 Pancreatic Neoplasms 130 Squamous Cell Carcinoma of Head and Neck 127 Ovarian Neoplasms 117 Melanoma 98 Carcinoma, Renal Cell 94 Recurrence 87 Stomach Neoplasms 81 Precursor Cell Lymphoblastic Leukemia-Lymphoma 80 Carcinoma, Hepatocellular 80 Lymphoma, Non-Hodgkin 79 Head and Neck Neoplasms 79 Lymphoma 78 Glioblastoma 78 Triple Negative Breast Neoplasms 76 Lymphoma, Large B-Cell, Diffuse 75 Urinary Bladder Neoplasms 69 Endometrial Neoplasms 68 Brain Neoplasms 68 Leukemia, Lymphocytic, Chronic, B-Cell 65 Uterine Cervical Neoplasms 62 Lymphoma, Follicular 62

Interventions

fludrocortisone acetate 1 enzalutamide 1 Prednisone 1 Hydrocortisone 1 Dexamethasone 1 Abiraterone Acetate 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Prostate Cancer Metastatic × 30 days × Clear all

NCT06136624 2026-05-05

OMAHA-003

Merck Sharp & Dohme LLC

Phase 3 Recruiting

Prostate Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡